Continued Versus Discontinued Oxytocin Stimulation of Labour
NCT ID: NCT02553226
Last Updated: 2020-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1200 participants
INTERVENTIONAL
2016-04-30
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The proposed study will investigate the effect of Syntocinon® (synthetic oxytocin) to induce labour. The hypothesis to be studied is that once the active phase of labour has commenced, Syntocinon® can be discontinued and the labour process will continue.
Design:
Double-blind randomised controlled multicentre trial
Setting:
Aarhus University Hospital, Denmark and Regional Hospital of Randers, Denmark
Population:
1200 women (600 in each group) stimulated in the latent phase of labour with oxytocin for induction
Methods:
The Syntocinon® infusion will be replaced with either continuous isotonic saline (placebo) or Syntocinon® infusion (control group), when the active phase of labour is reached.
Main outcome measures:
Caesarean section (primary outcome), tachysystole, neonatal asphyxia, birth experience
Perspective:
Syntocinon® is on the list high-alert medications and associated with complications for mother and child during labour. Reducing the duration of stimulation during labour may lower the number of asphyxial sequelae and the number of caesarean sections.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study
NCT01397630
Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study
NCT02859571
Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility
NCT02908126
Evaluation of the Modalities of Administration of Synthetic Oxytocin During Spontaneous Labor
NCT04935242
Induction of Labor With Oxytocin: When Should Oxytocin be Held?
NCT00957593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When the orificium ≥6 cm, regular painful contractions (≥3 per 10 minutes) and rupture of membranes participants will be randomised in a 1:1 ratio to either the control (continued Syntocinon®) or intervention (discontinued Syntocinon®) group using an Internet-based randomisation programme. The randomisation can only be performed when the woman consents to participation. Written consent can be given after the commencement of the Syntocinon® infusion, provided the woman previously has received sufficient information for her to give properly informed consent. Random block-sizes of 8 are used, and the participants will be stratified by site (Aarhus University Hospital, Randers Regional Hospital, Aalborg University hospital, or Sygehus Lillebælt Kolding), parity (nulliparous or parous) and indication for Syntocinon® infusion (induction or induction due to premature rupture of membranes).
The randomisation number corresponds to number of the project medicine (ampoule). The personnel of the delivery ward will administer the ampoules according to existing guidelines concerning medicine administration
Oxytocin stimulation protocol:
Existing national procedures prior to stimulation will be followed, including use of the existing checklists. No further examination will be done prior to inclusion and stimulation, no blood samples nor ECG to identify e.g. unknown QT-syndrome will be performed as this is never performed as a standard procedure prior to induction.
Latent phase: Stimulation will be given according to national DSOG guidelines7. Initially 20 ml/hour of 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl. The dose rate will be increased every 20 minutes by 20 ml/hour until appropriate uterine activity of 3-5 contractions per 10 minutes is achieved. The maximum allowed dose rate 180 ml/hour for induction of labour.
Active phase: The woman will be included in the study, when the active phase of labour is established (cervical dilatation ≥ 6 cm, ≥3 contractions per 10 minutes, and rupture of membranes). Randomisation is performed, and the infusion will be replaced by the trial solution, which will be either Syntocinon® at the same concentration, or a placebo infusion which will not contain Syntocinon®:
1. Control group; 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl infusion
2. Intervention group; 1ml 0,9% NaCl diluted in 1000ml 0,9% NaCl infusion. The infusion will be continued to achieve uterine activity of 3-5 contractions per 10 minutes. Maximum allowed dose is 180 ml/hour for induction. The procedure for administration of the trial solution is identical with the existing procedure.
Complications:
The infusion will be reduced or discontinued at any point of labour, if the following occur:
* Hyperstimulation (\>5 contractions per 10 minutes and non-reassuring CTG13). A management algorithm for this situation is made.
* Uterine contractions lasting 2 minutes or more
* Non-reassuring CTG (recurrent variable decelerations, fetal tachycardia or bradycardia, minimal to absent baseline variability, late decelerations)
* Suspicion of uterine rupture These conditions will be managed according to the guidelines of the local delivery wards.
Dystocia:
If there is failure to progress, defined as less than two cm dilation over 4 hours despite apparently adequate contractions and/or maximal infusion rates (Syntocinon® or placebo), the project medicine will be replaced with open-labelled Syntocinon® infusion. Stimulation will be given according to national DSOG guidelines7. Initially 20 ml/hour of 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl. The dose rate will be increased every 20 minutes by 20 ml/hour until appropriate uterine activity of 3-5 contractions per 10 minutes is achieved. The maximum allowed dose rate is180 ml/hour for induction.
Woman receiving open-labelled Syntocinon® infusion for 4 hours and continuous failure to progress: Consider caesarean section.
Unconcealment The primary investigator or a nominated deputy will at all time be able to break the randomisation code and reveal the allocation group, if needed. The Internet Based Randomisation Programme will provide the primary investigator or a nominated deputy with this possibility. (A 24/7 availability of the allocation group is thereby provided).
Side effects and risks:
Persistent failure to progress can be expected in 8-46% of the participants in the placebo group versus 3-17% in the control group. 3 4 5 6 Based on data from the pilot study, the risk of caesarean section is expected to be 15% in the placebo group versus 22% in the control group. According to the pilot study and previous studies 3 4 5 6, the maternal and neonatal complications in the placebo group are expected to be lower than in the control group.
All participants are monitored with continuous electronic fetal heart rate monitoring during labour to detect complications such as uterine tachysystole and non-reassuring/pathological fetal heart rate, in accordance with national guidelines.
The personnel of the delivery ward are responsible for registering of adverse reactions and adverse events.
Following adverse reactions and event will be registered immediately in the electronic medical journal of the patient:
* Cesarean delivery
* Postpartum hemorrhage \>500 ml
* Manual placenta removal
* Rupture of the anale sphincter
* Urine retention
* Neonatal: pH \<7,10 and/or Apgar score ≤ 6 at 5 minutes
Following serious adverse reactions and adverse events will be also registered immediately in the electronic medical journal of the patient:
* Intrauterine dead during labour
* Maternal amniotic fluid emboli or thromboembolic event
* Maternal cardiac arrest
* Maternal Pulmonary edema
* Uterine rupture The women will be followed for at least 3-6 hours postpartum (termination of project medicine) according current practice on the delivery ward.
The product resume of Syntocinon® will be used as reference to determine whether a Serious Adverse Reaction is expected or unexpected. Primary investigator or a nominated deputy will go through the participants medical file 7-30 days postpartum during data management and Primary investigator will ensure that all relevant information about suspected serious unexpected adverse reactions that are fatal or life-threatening is recorded and reported as soon as possible to the competent authorities concerned, and to the Ethics Committee, and in any case no later than seven days after the knowledge such a case, and that relevant follow-up information is subsequently communicated within an additional eight days.
Primary investigator will report to the competent authorities concerned and to the Ethics Committee concerned all other suspected unexpected serious adverse reactions as soon as possible but within a maximum of 15 days of first knowledge.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continued group
Recieve routine treatment with oxytocin according to the danish national guidelines.
Oxytocin
Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
discontinued group (placebo)
The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
Placebo
Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Placebo
Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cervical dilatation \> 4 cm
* Non-cephalic presentation
* Multiple gestation
* Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon® initiation
* Fetal weight estimation \> 4500 g (clinical or ultrasonic)
* Subject declines participation
* Gestational age less than 37 completed weeks
Definition: Stimulation with Syntocinon® following Premature Rupture of membranes (PROM) is induction of labour if there is no cervical change prior to starting the infusion, whereas stimulation with Syntocinon after PROM but following the establishment of significant cervical change is augmentation.
18 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Randers Regional Hospital
OTHER
Aarhus University Hospital
OTHER
Kolding Sygehus
OTHER
Aalborg University Hospital
OTHER
Herning Hospital
OTHER
Rigshospitalet, Denmark
OTHER
University of Amsterdam
OTHER
Hillerod Hospital, Denmark
OTHER
Odense University Hospital
OTHER
Hvidovre University Hospital
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niels Uldbjerg, DMSc
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Pinar Bor, PhD
Role: PRINCIPAL_INVESTIGATOR
Regionalhospital Randers
Julie Glavind, PhD
Role: PRINCIPAL_INVESTIGATOR
Regionalhospital Randers
Philip Steer, BSc
Role: PRINCIPAL_INVESTIGATOR
Imperial College, London, England
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, Aarhus N, Denmark
Aalborg University Hospital
Aalborg, , Denmark
Rigshospitalet
Copenhagen, , Denmark
Regionshospitalet Herning
Herning, , Denmark
Nordsjællandshospital
Hillerød, , Denmark
Hvidovre Hospital
Hvidovre, , Denmark
Sygehus LIllebælt
Kolding, , Denmark
Odense University Hospital
Odense, , Denmark
Department of Gynecology and Obstetrics
Randers, , Denmark
Academic Medical Center
Amsterdam, Amsterdam-Zuidoost, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boie S, Glavind J, Uldbjerg N, Steer PJ, Bor P; CONDISOX trial group. Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial. BMJ. 2021 Apr 14;373:n716. doi: 10.1136/bmj.n716.
Boie S, Glavind J, Uldbjerg N, Bakker JJH, van der Post JAM, Steer PJ, Bor P. CONDISOX- continued versus discontinued oxytocin stimulation of induced labour in a double-blind randomised controlled trial. BMC Pregnancy Childbirth. 2019 Sep 2;19(1):320. doi: 10.1186/s12884-019-2461-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01102015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.